Stockwinners Market Radar for April 02, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:15 EDT Cathie Wood's ARK Investment bought 190K shares of PacBio today

19:56 EDT Rambus CEO sells $899K in common stock - In a regulatory filing, Rambus disclosed that its CEO Luc Seraphin sold 15K shares of common stock on April 2nd in a total transaction size of $899K.

19:50 EDT U Power LTD trading halted, news pending

18:57 EDT Dollar Tree CFO buys $244.8K in common stock - In a regulatory filing, Dollar Tree disclosed that its CFO Jeffrey Davis bought 1.8K shares of common stock on April 1st in a total transaction size of $244.8K. Shares of Dollar Tree are up 0.9% afterhours at $135.95.

18:10 EDT Vanda Pharmaceuticals' Fanapt receives FDA approval - Vanda Pharmaceuticals announced that the U.S. Food and Drug Administration has approved Fanapt tablets for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. Fanapt is an atypical antipsychotic agent that has been used for the acute treatment of patients with schizophrenia since its FDA approval in 2009. "Manic or mixed episodes associated with bipolar I disorder are highly complex conditions, which require a host of trusted options to meet individual patient needs. With over 100,000 patient years of experience, Fanapt is a familiar therapeutic agent that offers flexible dosing with a well-known safety profile. This FDA approval gives patients and service providers a new treatment option for managing bipolar I disorder," said Mihael H. Polymeropoulos M.D., Vanda's President, CEO and Chairman of the Board.

18:00 EDT BMW reports Q1 U.S. sales up 2.4% year-over-year - BMW of North America reported Q1 sales results for the BMW and MINI brands in the U.S. In the first quarter of 2024, BMW brand sales in the U.S. totaled 84,475 vehicles, a 2.4% increase from the 82,466 vehicles sold in the first quarter of 2023. With the addition of the BMW i5 at the end of last year, BMW now offers four fully electric models in the U.S. - the BMW i4, BMW i5, and BMW i7 Sedans, and the BMW iX Sports Activity Vehicle. In the first first quarter of 2024, the company sold 10,713 electric vehicles, accounting for approximately 12.7% of total U.S. sales. MINI sales in the U.S. totaled 6,369 vehicles in the first quarter of 2024, a decrease of 12.6% vs the 7,284 vehicles sold in the first quarter of 2023. The change in sales volume for the brand this quarter is attributed directly to a planned model changeover as MINI readies for the launch of an entirely new product portfolio later this year.

17:49 EDT CalAmp says FY24 to be 'another successful year' - CEO Sherman Miller stated: "Across our operations, we are focused on meeting this demand, as we continue to identify opportunities to extend our market reach. We are also making significant investments in our operations to drive innovation and more efficient production and support our ability to add capacity, including cage-free opportunities. We have a strong balance sheet that provides us with the flexibility to fund our growth initiatives, including potential acquisitions. We believe fiscal 2024 will be another successful year for the Company, and we look forward to the opportunities ahead for Cal-Maine Foods."

17:35 EDT Intel shares fall amid widening operating loss at Foundry unit - Intel is giving a more detailed picture of its finances as part of a turnaround plan by Chief Executive Officer Pat Gelsinger. He's breaking out the results from the factory network as a step toward having it operate more independently. The business is seeking to make chips for other companies, and giving it some separation from the rest of Intel is vital to that strategy. Shares of semiconductor giant Intel are falling post-close on Tuesday after disclosing that revenue from its Foundry unit had sales of $18.9B in 2023, as compared to $27.5B in 2022, the company said in a regulatory filing on Tuesday. "We had an operating loss of $7.0B, compared to an operating loss of $5.2 billion in 2022," said the company in the filing. Dave Zinsner, Intel's CFO said in part "we expect to accelerate on our path toward achieving our ambition of 60% non-GAAP gross margins and 40% non-GAAP operating margins 2030. ...improved cost competitiveness will help us deliver process technology, product and foundry leadership while driving significant financial upside for Intel and our owners."

17:01 EDT Centogene receives noncompliance notification from Nasdaq - Centogene announced that it received a notification letter from Nasdaq indicating that the company was not in compliance with the minimum bid price requirement set forth in Rule 5450(a)(1) of the Nasdaq Listing Rules since the closing bid price for the company's common shares listed on Nasdaq was below $1.00 for 30 consecutive business days. Nasdaq Rule 5450(a)(1) requires the shares to maintain a minimum bid price of $1.00 per share, and Nasdaq Rule 5810(c)(3)(A) provides that failure to meet such a requirement exists when the bid price of the shares is below $1.00 for a period of 30 consecutive business days.

16:35 EDT Edible Garden announces plan for 1-for-20 stock split effective Friday, April 5 - Edible Garden announced a planned reverse stock split of its shares of common stock at a ratio of 1-for-20. The reverse stock split will take effect as of 12:01 a.m. ET, on Friday, April 5 and shares of Edible Garden will trade on a post-split basis on Nasdaq under the existing trading symbol, "EDBL," at the market open on April 5. At the Company's special meeting of stockholders held November 6, 2023, stockholders approved an amendment to the Company's certificate of incorporation to implement a reverse stock split in a range of 1-for-5 to 1-for-50, and granted the board of directors the authority to implement and determine the exact split ratio within such range, which was subsequently set by the board at 1-for-20. Following the reverse stock split, the new CUSIP number of the common stock will be 28059P303, with the par value per share of common stock remaining at $0.0001. A proportionate adjustment will be made to the per-share exercise prices and number of shares issuable under all outstanding warrants and equity awards.

16:29 EDT Nanobiotix completes dose escalation of of radioenhancer NBTXR3 study - Nanobiotix announced completion of the dose escalation part of a Phase 1 study evaluating potential first-in-class radioenhancer NBTXR3 for patients with non-small cell lung cancer that cannot be treated by surgery inoperable , and has come back or recurrent, whom have previously been treated with definitive radiation therapy and are amenable to re-irradiation. The Phase 1 study is being conducted by The University of Texas MD Anderson Cancer Center as part of an ongoing strategic collaboration with Nanobiotix. "NBTXR3 is designed as a product candidate with the potential to improve treatment outcomes for patients with cancer in any setting where radiotherapy is a part of the treatment regimen. While these patients experience different cancer types and are each faced with unique challenges, what they share is an urgent need for therapeutic innovation with the chance to make a difference," said Louis Kayitalire, MD, Chief Medical Officer at Nanobiotix. "We believe the injection feasibility and favorable safety profile we have observed from the completed dose escalation part of this Phase 1 lung cancer study could pave the way for additional clinical development of NBTXR3 for patients with inoperable, recurrent lung cancer and patients amenable to re-irradiation."

16:24 EDT View Inc. in pact with Cantor Fitzgerald and RXR to go private - View announced it reached an agreement with Cantor Fitzgerald, RXR Realt RXR" , and certain of the Company's stakeholders on the terms of a financial restructuring that is designed to strengthen the firm's balance sheet and better position View for the future. To ensure a timely process, View and certain of its subsidiaries will commence prepackaged Chapter 11 cases in the District of Delaware. During this time, View expects its operations to continue as normal. View also expects that trade claims will be unaffected, orders will continue to be fulfilled, and customers will continue to be supported. The Company expects to obtain court approval for the Proposed Transaction within 45 days of April 2, 2024. Shortly thereafter, View expects to emerge as a privately held company with a reorganized board of directors, whereby Howard Lutnick, Chairman & CEO of Cantor Fitzgerald, and Scott Rechler, Chairman & CEO of RXR, will provide support and guidance to View on its operational structure and corporate strategy. "Today's announcement marks the culmination of a thorough strategic review of our business operations to help ensure we have the proper capital structure going forward," said Dr. Rao Mulpuri, CEO of View. "With the support of Cantor Fitzgerald and RXR, we intend to maximize our business potential with increased financial stability and be better positioned to increase our presence across the real estate ecosystem."

16:15 EDT OneMedNet CEO Paul Casey to retire, Aaron Green to succeed - OneMedNet announced that its president, Aaron Green, has assumed the role of president and CEO, in addition to an appointment to OneMedNet's board of directors. Green will succeed CEO, Paul Casey, who has announced his retirement and who will continue to serve on the board. Green has more than 20 years of experience. As president and CEO, Green will lead all facets of OneMedNet's business involving its iRWD offering, including R&D, product, strategy, and sales across global markets.

16:14 EDT Pulmonx appoints Mehul Joshi CFO - Pulmonx Corporation announced the appointment of Mehul Joshi as Chief Financial Officer, effective April 3 . He succeeds John McKune, who has served as the Company's Interim Chief Financial Officer since October 10, 2023, and will transition to his prior role as Vice President, Corporate Controller. "Mehul is an exceptionally accomplished financial executive and I am excited to welcome him to our leadership team. His proven track record of leading global finance teams within large, diversified companies makes him the right fit for Pulmonx as we continue to execute on our multifaceted growth strategies and I look forward to working closely with him," said Steve Williamson, President and Chief Executive Officer. "I would also like to thank John McKune for stepping into the role of Interim Chief Financial Officer and for his continued leadership on the finance team."

16:07 EDT Intel outlines Foundry business financial framework for 2024 and beyond - Intel outlined a new financial reporting structure that is aligned with the company's previously announced foundry operating model for 2024 and beyond. This new structure is designed to drive increased cost discipline and higher returns by providing greater transparency, accountability and incentives across the business. To support the new structure, Intel provided recast operating segment financial results for the years 2023, 2022 and 2021. The company also shared a targeted path toward long-term growth and profitability of Intel Foundry, as well as clear goals for driving financial performance improvement and shareholder value creation. The new operating model establishes a foundry relationship between Intel Foundry, the company's manufacturing organization, and Intel Products, comprised of the company's product business units. Launched at its inaugural Direct Connect event in February, Intel Foundry is the world's first systems foundry for the AI era, offering full-stack optimization from the factory network to software. Beginning with the first quarter 2024, the company will present segment results aligned to the following operating segments: Client Computing Group (CCG); Data Center and AI (DCAI); Network and Edge (NEX); Intel Foundry; Altera, an Intel Company (formerly Intel's Programmable Solutions Group); Mobileye; and Other. CCG, DCAI and NEX will collectively be referred to as Intel Products; Altera, Mobileye and Other will collectively be referred to as All Other. The transition to the new operating model is expected to enable Intel Foundry to achieve profitable growth and unlock unrealized value across Intel's approximately $100 billion in capital assets. It will also create significant efficiency and cost savings opportunities across both Intel Foundry and Intel Products. As part of today's news, Intel also announced the appointment of Lorenzo Flores as chief financial officer of Intel Foundry, effective April 8, 2024. Flores possesses nearly 30 years of financial experience in semiconductors and technology, including most recently as the chief financial officer of Xilinx. This complements the earlier appointment of Mark Henninger as the chief financial officer of Intel Products. Both will report to Zinsner.

16:03 EDT Cambium Networks appoints Jacob Sayer as CFO - Cambium Networks (CMBM) announced the appointment of Jacob Sayer as CFO, effective April 8. He will be responsible for Cambium's financial strategies and will lead the global finance organization, including planning, treasury, tax, reporting, and investor relations. Jacob will succeed John Becerril, who is currently acting CFO following the January 2024 departure of Andrew Bronstein. John will remain as Cambium's Global Controller and principal accounting officer.Sayer brings a wealth of finance, operational, and strategic planning experience to Cambium Networks, most recently with a variety of challenging finance and business unit CFO roles at $9N enterprise value NYSE-listed industrial technology company Sensata Technologies Holding (ST). Jacob has experience in business and financial strategy and financial operations, as well as acquisition integration and transformation. He brings a proven track record of driving strong financial results and instilling financial and operational discipline.

15:52 EDT Capcom's 'Dragon's Dogma 2' sells over 2.5M units - Capcom (CCOEY) announced that worldwide sales of "Dragon's Dogma 2" surpassed 2.5M units. The game, which released on March 22, 2024, is available on PC, PlayStation 5 (SONY) and Xbox Series X/S (MSFT). Since the release of the original "Dragon's Dogma" in 2012, the series has exceeded 10M cumulative unit sales. Reference Link

15:18 EDT StoneBridge Acquisition Corp trading halted, volatility trading pause

14:52 EDT Lonza names Wolfgang Wienand CEO - The Board of Directors of Lonza announced that Wolfgang Wienand has been appointed Chief Executive Officer, CEO, and will join the company during the summer of 2024. Wolfgang is currently CEO of the Swiss contract development and manufacturing organization CDMO Siegfried Holding , a role he has held since 2019. Prior to this, Wolfgang first served as Chief Scientific Officer and then as Chief Strategy Officer in Siegfried's executive leadership team. Before joining Siegfried in 2010, Wolfgang held a series of increasingly senior positions at the German specialty chemicals company Evonik Industries. Wolfgang will succeed Albert M. Baehny, who took on the additional responsibility of CEO on an ad interim basis in October 2023 while the search for a permanent CEO took place. Albert will remain at Lonza for a transition period during the summer, before retiring from the company.

14:20 EDT Lam Research Chairman Talwalkar sells over $857K in company shares - Chairman of Lam Research Abhijit Talwalkar disclosed the sale of 882 shares of company stock at $972.03 per share on April 1, for a total transaction amount of $857,330.

13:22 EDT A SPAC I Acquisition Corp trading resumes

12:48 EDT Endeavor Group Holdings trading resumes

12:37 EDT Honda reports March U.S. sales up 11.8% to 130,504 units - Honda said that Honda brand reached 118,536 units in March up 14.9%, the brand's best month since 2021. Honda saw over 20% growth in Q1 on total sales of 303,451 units.

12:34 EDT Silver Lake acquires Endeavor Group for $27.50 per share or $13B - Endeavor Group announced that it has entered into a definitive agreement to be acquired by Silver Lake, in partnership with the Endeavor management team and additional anchor investors. Under the terms of the agreement, Silver Lake will acquire 100% of the outstanding shares it does not already own, other than rolled interests. Endeavor stockholders will receive $27.50 per share in cash. Endeavor is being acquired at an equity value of $13B. "Silver Lake believes that when consolidating all of TKO's (TKO) value into Endeavor, the combined total enterprise value of $25 billion will make this the largest private equity sponsor public-to-private investment transaction in over a decade, and the largest ever in the media and entertainment sector," Endeavor said in a statement. TKO is not party to this transaction and will remain a publicly traded company. The transaction is expected to close by the end of the first quarter of 2025.

12:18 EDT Endeavor Group Holdings trading halted, news pending

12:10 EDT Cal-Maine reports positive case of avian influenza at Texas facility - Cal-Maine Foods reported that one of the company's facilities located in Parmer County, Texas, tested positive for highly pathogenic avian influenza, resulting in depopulation of approximately 1.6M laying hens and 337,000 pullets, or approximately 3.6% of its total flock as of March 2. Production at the facility has temporarily ceased as Cal-Maine follows the protocols prescribed by the USDA. "There is no known risk related to HPAI associated with eggs that are currently in the market and no eggs have been recalled," the company added.

12:07 EDT Mitsubishi reports Q1 North America sales up 35.7% to 8,403 units - Mitsubishi Motors North America reported Q1 sales of 28,403, up 35.7% over Q1 of 2023. "Assisted by dealer new-vehicle inventory stocks returning to near-pre-pandemic levels, the brand and its dealer partners achieved their highest quarterly sales total since Q1 2020," the company said in a statement.

12:05 EDT General Motors reports Q1 deliveries down 1.5% to 594,233 vehicles - General Motors and its dealers increased retail sales by 6% year-over-year and delivered 594,233 vehicles in the U.S. in Q1, down 1.5% year-over-year due to lower fleet deliveries. The company said, "Our brands are all performing well. GM gained retail market share year-over-year with strong mix and pricing, our inventories are in good shape heading into the spring, and production and deliveries of Ultium Platform EVs are rising, led by the Cadillac LYRIQ. We're on plan."

12:00 EDT GE Aerospace falls -18.2% - GE Aerospace is down -18.2%, or -$31.89 to $143.47.

12:00 EDT Daily S&P Biotech Bear 3x Shares rises 8.4% - Daily S&P Biotech Bear 3x Shares is up 8.4%, or 63c to $8.16.

12:00 EDT Montrose Environmental rises 12.1% - Montrose Environmental is up 12.1%, or $4.79 to $44.19.

11:26 EDT Establishment Labs says FDA schedules preapproval inspection for Motiva facility - In a regulatory filing, Establishment Labs disclosed that On April 2, during the J.P. Morgan MedTech 2024 CEO Conference Call Series, the company is announcing that the FDA has scheduled the PMA preapproval inspection of the company's manufacturing facility for Motiva Implants. The inspection by the FDA is scheduled to take place during Q2 of 2024.

11:15 EDT Mazda reports North America sales up 6.7% to 37,119 vehicles - Mazda North America reported total March sales of 37,119 vehicles, an increase of 6.7% compared to March 2023. Year-to-date sales totaled 100,103 vehicles sold, an increase of 13.3% compared to the same time last year.

11:15 EDT QuidelOrtho withdraws FDA 510(k) submission for RVP4+ assay - QuidelOrtho said earlier that upon reviewing the performance of the Savanna RVP4+ assay against the clinical market's expectations, a decision was made to withdraw the current FDA 510(k) submission for the Savanna RVP4+ assay. "Data generated over a 9-month period for the four viruses targeted by the assay initially showed great promise, which led to the FDA submission in July 2023. However, the final dataset, submitted in February 2024, did not meet our expectations. In addition, during the pendency of the submission, the company has continued to develop the next-generation RVP4+ assay. The company anticipates the new multiplex assay to be commercially available during the 2024/2025 respiratory season. QuidelOrtho remains committed to expanding the Savanna platform menu. The company is making good progress on a sexually transmitted infection panel and expects to begin clinical trials later in the second quarter."

10:37 EDT Acorda sinks 86% after filing Chapter 11, selling assets - The shares are down $11.34 to $1.98 in morning trading.

10:16 EDT Acorda Therapeutics trading halted, volatility trading pause

10:00 EDT Direxion Daily Semiconductor Bear 3X Shares rises 6.8% - Direxion Daily Semiconductor Bear 3X Shares is up 6.8%, or 21c to $3.32.

10:00 EDT Daily S&P Biotech Bear 3x Shares rises 6.9% - Daily S&P Biotech Bear 3x Shares is up 6.9%, or 52c to $8.05.

10:00 EDT GE Aerospace falls -19.7% - GE Aerospace is down -19.7%, or -$34.53 to $140.83.

09:57 EDT Avangrid receives federal Record of Decision for New England Wind - Avangrid announced that it has received the federal Record of Decision from the Department of the Interior for New England Wind. The ROD represents a significant permitting milestone that brings the lease area closer to full federal approval for construction, with the Construction and Operations Plan Approval anticipated for July 2024. Issuance of the ROD by the Department of the Interior comes after years of robust stakeholder engagement with Tribal Nations, members of local residential and fishing communities, and other ocean users. New England Wind, consisting of the New England Wind 1 and New England Wind 2 projects, has the potential to create thousands of jobs and provide enough clean, reliable energy to power nearly 1 million homes and businesses in the region. As the leading offshore wind developer in the United States, Avangrid is spearheading the development of the first-in-the-nation Vineyard Wind 1 project, currently under construction and delivering clean, reliable power to 30,000 homes and businesses in Massachusetts.

09:54 EDT Logistic Properties of The Americas trading resumes

09:49 EDT Logistic Properties of The Americas trading halted, volatility trading pause

09:47 EDT Direxion Daily Semiconductor Bear 3X Shares rises 5.5% - Direxion Daily Semiconductor Bear 3X Shares is up 5.5%, or 17c to $3.28.

09:47 EDT Biotie Therapies rises 7.6% - Biotie Therapies is up 7.6%, or 57c to $8.06.

09:47 EDT Cazoo Group trading halted, volatility trading pause

09:47 EDT PVH Corp. falls -20.6% - PVH Corp. is down -20.6%, or -$28.77 to $110.97.

09:42 EDT Zapata Computing Holdings Inc trading resumes

09:38 EDT CXApp Inc trading resumes

09:36 EDT Keyarch Acquisition Corp trading resumes

09:35 EDT SHLT Stock trading resumes

09:31 EDT Winvest Acquisition Corp trading halted, volatility trading pause

09:30 EDT American Oncology Network Inc trading halted, volatility trading pause

09:30 EDT SHLT Stock trading halted, volatility trading pause

09:17 EDT Crypto names slide in pre-market as bitcoin falls to $65,000 - Stocks levered to bitcoin prices are trading sharply lower with the cryptocurrency falling from above $69,500 to a one-week low of about $65,000 overnight. In pre-market trading, Bit Digital (BTBT) is down about 8% at $2.54 per share, Riot Blockchain (RIOT) is down 5% at $10.93, Marathon Digital (MARA) is down 6% at $20.33, MicroStrategy (MSTR) is down 8% at $1,503 and Coinbase Global (COIN) is down 5% at $238.30.

09:10 EDT Tesla falls 6% to $163.99 after Q1 delivery report

09:08 EDT Tesla produces 433,000 vehicles, delivers 387,000 vehicles in Q1 - In the first quarter, Tesla produced over 433,000 vehicles and delivered approximately 387,000 vehicles. We deployed 4,053 MWh of energy storage products in Q1, the highest quarterly deployment yet. Decline in volumes was partially due to the early phase of the production ramp of the updated Model 3 at our Fremont factory and factory shutdowns resulting from shipping diversions caused by the Red Sea conflict and an arson attack at Gigafactory Berlin.

09:07 EDT Jakks Pacific's Disguise enters agreement with Sony Pictures Consumer Products - Disguise, the global costume division of leading toy and consumer products manufacturer JAKKS Pacific (JAKK), announced that it has entered into an agreement with Sony (SONY) Pictures Consumer Products, for its costume division Disguise, to produce costumes based on the new film Ghostbusters: Frozen Empire, which is currently playing in theaters. Disguise will design, market, manufacture and distribute costumes, costume accessories and inflatables for the movie commencing in 2024.

09:05 EDT Euroseas announces one-year time charter contract for M/V Synergy Antwerp - Euroseas announced a time charter contract for its 4,250 teu intermediate containership, M/V Synergy Antwerp, for a minimum period of 11.5 to a maximum period of 14 months at the option of the charterer, at a gross daily rate of $26,500. The charter commenced on April 2, 2024, after the vessel successfully completed its scheduled drydock and special survey, along with certain retrofits including the installation of a number of "energy saving devices". The latter are expected to improve her consumption in the commercial speed range by about 25%. On that basis, the vessel will emit about 9,800 metric tons of CO2 less per annum. Aristides Pittas, Chairman and CEO of Euroseas commented: "We are pleased to announce that M/V Synergy Antwerp was chartered for about a year to a top-tier charterer at a very profitable rate of $26,500/day, following the completion of its drydock and retrofits. The charter rate represents a strong increase compared to last done, indicating charterer's interest in more modern, energy efficient vessels; it is expected to contribute about $6.5 million of EBITDA over the minimum contracted period and increases our 2024 charter coverage to about 80%. This is the third vessel from our fleet undergoing retrofits as part of our ongoing efforts to modernize our fleet and reduce our carbon footprint."

09:05 EDT OpenText selected by Coroplast Group as e-invoicing provider for Poland - OpenText announced that it has been selected by Coroplast Group, a leading manufacturer in the fields of Technical Adhesive Tapes, Wires & Cables, and Wire Harnesses, as its e-invoicing provider for Poland. OpenText's e-invoicing solutions will empower the growing global company to confidently manage mandatory governmental requirements in Poland, partnering toward the goals of a seamless connection to the Polish KSeF-portal and compliance with the local mandate. As part of the European Commission's universal e-invoicing mandate businesses operating in Poland must comply and establish the necessary infrastructure. With OpenText as its e-invoicing provider, Coroplast Group can feel confident in its compliance while also reaping the benefits of the platform, such as streamlined document processing, real-time invoice information for business management, and expedited VAT returns.

09:04 EDT Hyundai Motor America reports total March sales of 76,920 units, up 2% y/y - Hyundai Motor America reported record-breaking total March sales of 76,920 units, a 2% increase compared with March 2023. Hyundai set total sales records in March for IONIQ 5 (+58%), Tucson PHEV (+62%), Tucson HEV (+48%) and Palisade (+58%). Hyundai EV sales increased 100% and all eco-friendly vehicle sales combined hit 11,485 units, a 35% increase. Fleet volume was 11% of total sales.

09:03 EDT Beacon to acquire Smalley & Company, terms undisclosed - Beacon announced that it signed a purchase agreement to acquire Smalley & Company, headquartered in Denver, Colorado with eleven locations in Colorado, Arizona, California, Nevada, New Mexico and Utah. Smalley is a privately held company, which is 100% owned by an Employee Stock Ownership Plan and Trust, or ESOP. Closing the contemplated transaction requires a majority vote of the plan's Participants giving the ESOP Trustee authorization to approve the sale. Smalley & Company has been providing contractors, design professionals, and owners with tailored sealant and waterproofing solutions since 1967. Smalley & Company has become an industry leader through its dedication to being a vital link in the supply chain to contractors that perform a wide range of applications in the new construction and restoration markets.

09:03 EDT Select Medical sign joint venture agreement with UF Health Jacksonville - Select Medical announced it has signed a joint venture agreement with UF Health Jacksonville to establish a 48-bed inpatient rehabilitation hospital within UF Health North in Jacksonville, Florida. The joint venture hospital-in-a-hospital will be branded UF Health Rehabilitation Hospital - North and is expected to open in summer 2024 in the new tower of UF Health North. It will be managed by Select Medical.

09:01 EDT Abbott receives FDA approval for TriClip - Abbott announced that the U.S. FDA has approved the company's first-of-its-kind TriClip transcatheter edge-to-edge repair system that's specifically designed for the treatment of tricuspid regurgitation, or a leaky tricuspid valve. This approval follows the recent recommendation of the Circulatory System Devices Panel of the Medical Devices Advisory Committee for the FDA, whose vote confirmed 13 to 1, with 0 abstention that the benefits of TriClip outweighed the risks.

08:47 EDT Surge Copper announces C$3.8M investment by African Rainbow - Surge Copper (SRGXF) announces that it has entered into a subscription agreement for a private placement financing with a new cornerstone strategic investor, African Rainbow Minerals Limited (AFBOF). Under the terms of the Strategic Placement, ARM, through its wholly-owned subsidiary ARM Copper Company Proprietary Limited, will subscribe for 39,608,708 common shares of Surge at C$0.095 per Strategic Placement Common Share, representing an approximately 18% premium to the 20-day volume weighted average price of the Company's common shares on the TSX Venture Exchange as at April 1, 2024, for gross proceeds of approximately C$3,762,827. Upon completion of the Strategic Placement, ARM will own 15.0% of Surge's issued and outstanding common shares on a non-diluted basis.

08:44 EDT Rivian Q1 vehicles deliverd 13,588, reaffirms guidance for FY24 - Rivian Automotive announced production and delivery totals for the quarter ending March 31. The company produced 13,980 vehicles at its manufacturing facility in Normal, Illinois and delivered 13,588 vehicles during the same period. Production and delivery results during the first quarter of 2024 were in line with Rivian's expectations. For the full year 2024, management is reaffirming guidance for annual production of 57,000 total vehicles. The company also announced that on May 7th, after market close, it will release its first quarter 2024 financial results

08:42 EDT LiveOne subsidiary Drumify launches subscription marketplace - Drumify, a subsidiary of LiveOne, announced that it launched its subscription model, Drumify 3.0. The subscription model is designed to convert ~70% of Drumify's customer base into recurring subscribers, increasing customer lifetime value and overall revenue. "We have been working around the clock on our subscription platform for over a year to not just compete with Splice, but help educate creatives on copyright ownership and building long-term wealth. We're so excited to finally put it out into the world, and the response so far has been overwhelming," said Aidan Crotinger, Founder of Drumify.

08:39 EDT Aditxt in pact to acquire Appili Therapeutics for 5.6c per share - Aditxt (ADTX) announced that it has entered into a definitive arrangement agreemen to acquire Appili Therapeutics (APLIF) . Under the Arrangement Agreement, Aditxt's wholly owned subsidiary, Adivir, agreed to acquire all issued and outstanding Class A common shares of Appili through a court-approved plan of arrangement under the Canada Business Corporations Act...The U.S. FDA's approval of LIKMEZ highlighted Appili's capacity to identify and develop significant opportunities within the infectious disease domain. Appili licensed the manufacturing and commercialization rights in the U.S. and other selected territories to Saptalis Pharmaceuticals ....The Transaction will be effected through a court-approved plan of arrangement under the Canada Business Corporations Act. Under the terms of the Arrangement Agreement, Adivir will acquire all of the issued and outstanding Appili Shares, with each Appili Shareholder receiving 0.002745004 of a share of common stock of Aditxt and $0.0467 for each Appili Share held representing total consideration per Appili Share of approximately $0.0561 based on the closing price of Aditxt stock on March 28, After giving effect to the Transaction, Appili Shareholders will hold approximately 19.99% of the issued and outstanding Aditxt Shares based on the currently issued and outstanding Aditxt Shares... In connection with the Transaction, each outstanding option and warrant of Appili will be cashed out based on the implied in-the-money value of the Transaction Consideration. In connection with the Transaction Aditxt will: agree to repay no less than 50% in outstanding senior secured debt at the closing of the Transaction and to repay the remaining outstanding senior secured debt by no later than December 31, 2024; cquire all of Appili's remaining outstanding liabilities and indebtedness; and agree to satisfy certain payables of Appili at Closing as further detailed in the Arrangement Agreement. The Transaction is subject to the approval of at least two-thirds of the votes cast at the special meeting of the Appili Shareholders, which is expected to be held before the end of calendar Q2 2024 to approve the Transaction.

08:37 EDT NetSol Technologies achieves AWS foundational technical review badges - NETSOL Technologies (NTWK) has announced its achievement of the Amazon (AMZN) Web Services, AWS, Foundational Technical Review badges. This achievement is in recognition of five of NETSOL's cloud-based, API-first solutions that are part of Appex Now - the Company's marketplace of products designed for the global credit, finance and leasing industry. "We're thrilled to earn the AWS Foundational Technical Review badges," said Najeeb Ghauri, Founder and CEO of NETSOL Technologies, Inc. "This achievement underscores our dedication to delivering cutting-edge cloud solutions that meet the highest industry standards. Our clients can be confident that they're partnering with a company that has proven its capabilities in architecting top-tier AWS-based solutions."

08:35 EDT ToughBuilt obtains purchase order financing to fuel supply chain initiatives - ToughBuilt Industries announced its strategic alliance with King Trade Capital, securing a line of credit expected to significantly enhance the Company's procurement, direct import, and order fulfillment capabilities. The Company believes this line of credit will ensure its commitment to existing and new retail partners and strengthen its relationships with key retail partners and factories, translating to enhanced operational efficiency, growth, and improved cost-effectiveness. Michael Panosian, ToughBuilt's Co-Founder and Chief Executive Officer, remarked, "We believe our arrangement with King Trade Capital will fuel our agility in sourcing and meeting demand for our current and new customers. Our relationship will allow us to fulfill and optimize our direct import orders, as needed." Panosian continued, "We intend for this alliance to demonstrate the Company's growing financial maturity as we follow our path to cashflow positivity and continue to press toward greater shareholder value and profitability."

08:35 EDT GlucoTrack announces increase sensory longevity for CBGM - Glucotrack and The Technology Partnership, TTP, announced the completion of computational modeling for Glucotrack's implantable Continuous Blood Glucose Monitor, CBGM, suggesting sensor longevity beyond three years, a year longer than the Company previously announced. Glucotrack has engaged TTP for the development of computational modeling, which addresses enzyme longevity for use in long-term implantable electrochemical sensors. "TTP is well versed in supporting clients with creating breakthrough medical technology solutions," said Paul Goode, PhD, CEO of Glucotrack. "This collaboration has enhanced our development program, and the projected increase in sensor longevity to beyond three years further demonstrates that our technology is truly differentiated in the glucose monitoring space. This achievement doesn't change our commercialization timing but instead paves the way for future generations of our system, which will be a truly long-term CBGM to people living every day with diabetes."

08:33 EDT PainReform reaches 50% enrollment in second part of Phase 3 trial of PRF-110 - PainReform announced it has reached the 50% enrollment target for the second part of Phase 3 clinical trial of PRF-110 in bunionectomy. In total, over 200 patients have been enrolled, of up to approximately 400 patients at eight clinical sites across the U.S. Ilan Hadar, Chief Executive Officer of PainReform, stated, "I am thrilled to announce that we have hit a critical milestone in our Phase 3 clinical trial of PRF-110 for bunionectomy, with 50% of the required participants now enrolled. Importantly, to date there have been no reported serious adverse events, underscoring PRF-110's potential safety gathered until today. We're on track to wrap up enrollment on schedule and are looking forward to sharing the early results in Q3 2024. We remain highly encouraged by the potential of PRF-110 to redefine the standard of care in the multibillion-dollar postoperative pain management market, as well as offering patients a compelling alternative to systemic opioids, which have contributed to the global opioid epidemic."

08:32 EDT Miller Industries announces $25M share repurchase program - Miller Industries announced that its Board of Directors has authorized a $25M share repurchase program. The repurchase program is intended to be compliant with Rule 10b-18 and has no expiration date, does not require the purchase of any minimum number of shares, and may be suspended, modified or discontinued at any time without prior notice.

08:27 EDT MaxCyte signs strategic platform license with Be BioPharma - MaxCyte and Be BioPharma announced the signing of a strategic platform license, SPL, to support the development of Be Bio's BCMs programs. Under the terms of the agreement, Be Bio obtains non-exclusive research, clinical and commercial rights to use MaxCyte's Flow Electroporation technology and ExPERT platform. In return, MaxCyte is entitled to receive annual licensing fees and program-related revenue. "We are thrilled to support Be Bio's pioneering efforts in the creation of Engineered B Cell Medicines," said Maher Masoud, President and CEO of MaxCyte. "Our technology and expertise will empower them to unlock the potential of human B cells to address the unmet medical needs of patients with genetic diseases, cancer, and beyond. This new class of therapies could be transformative, and we are excited to be part of this journey."

08:24 EDT Ocugen provides business update - Ocugen provided a general business update with certain financials for the year ending 2023. "In 2023, our diligent efforts laid the foundation for continued advancement towards our clinical and operational goals with a focus on our game-changing modifier gene therapy platform," said Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen. "2024 is already proving to be a pivotal year with considerable developments in our modifier gene therapy programs for blindness diseases, and an increased understanding of the value of these assets among our stakeholders. Promising initial OCU400 Phase 1/2 study results for RP patients have been recognized by the FDA through the RMAT designation, potentially accelerating our path to deliver this critical therapy. With the FDA's support, we feel confident that this trial will continue to demonstrate the benefits of our gene-agnostic mechanism utilizing a potential one-time treatment for life via a single sub-retinal injection."

08:20 EDT GrafTech board issues open letter to stockholders - GrafTech International announced that it has filed its definitive proxy statement and WHITE proxy card with the Securities and Exchange Commission with respect to its 2024 Annual Meeting of Stockholders to be held on May 9. Stockholders of record as of the close of business on March 13 will be entitled to vote at the Annual Meeting. GrafTech's Board of Directors also issued a letter to the Company's stockholders in connection with the filing. The letter, in-part, follows: "In advance of the upcoming Annual Meeting, you have an important decision to make regarding the composition of the Company's Board that could impact the future of the Company and the value of your investment. Nilesh Undavia, a private investor, has nominated himself for election to the Board. The Board does not endorse his candidacy and urges you to vote "FOR" the nominees recommended by the Board using the WHITE proxy card. The Board further urges you to DISCARD all blue proxy cards and materials sent to you by Mr. Undavia."

08:18 EDT Bitcoin Depot surpasses 8,000 signed bitcoin ATM locations - Bitcoin Depot announced it is set to surpass its ambitious goal of deploying 8,000 Bitcoin ATMs a few months ahead of schedule, having already secured contracts for over 8,000 locations. The achievement solidifies the Company's previously announced objective of having the largest installed fleet of BTMs in its history. Now, with over 8,000 locations signed, Bitcoin Depot just needs to install enough incremental Bitcoin ATMs to reach the previously announced goal of 8,000. In January and February of 2024 Bitcoin Depot signed over 1,600 total new locations to receive its Bitcoin ATMs.

08:17 EDT Bionano Genomics announces 9 poster presentations at AACR meeting - Bionano Genomics announced its participation in the American Association for Cancer Research, AACR, Annual Meeting 2024 with a broad range of content covering the utility of OGM for cell bioprocessing quality control, solid tumor and hematological malignancy cancer research. AACR's annual meeting brings together industry, medical, and academic professionals to discuss advances in cancer science and medicine. The AACR conference will be held April 5-10, 2024, in San Diego, California. "We are excited to participate in AACR's annual meeting, where data that will be shared will point to the continued expansion of OGM into clinical research applications for hematological malignancies and solid tumors and highlight progress toward our goal of making OGM an essential tool in the arsenal of cancer researchers. We believe cancer is a disease of structural variation and that OGM and VIA, our software solution which has added features for cancer research and analysis, have the potential to make an impact in the fight against cancer," commented Erik Holmlin, president and chief executive officer of Bionano.

08:15 EDT Olink announces availability of open access data library - Olink Holding AB announced the availability of an open access data library consisting of over 300,000 protein-disease risk associations, giving researchers a powerful new tool for revealing the biological mechanisms underlying 106 human diseases. In April 2023, the UK Biobank Pharma Proteomics Project released data produced from over 50,000 samples analyzed using the Olink Explore platform. The UKB-PPP is the largest population-scale proteomics study to date, yielding an unprecedented view into the biology of diseased and healthy individuals over a 10-year period. The derived data library is available within Olink Insight.

08:13 EDT electroCore expands intellectual property portfolio - electroCore announced that it has received patent issue notifications from the United States Patent and Trademark Office, USPTO. The two patents were issued on April 2, 2024, and relate to electroCore's non-invasive vagus nerve stimulation, nVNS, technology: US Patent No. 11,944,815 entitled "Non-Invasive Nerve Stimulation with Mobile Device" generally relates to a system for transcutaneously stimulating a nerve in a patient that includes a downloadable software application configured to wirelessly transmit a therapy regimen to a stimulator. US Patent No. 11,944,807 entitled "Vagal Nerve Stimulation for Treating Central Nervous System Disorders" generally relates to methods for treating central nervous disorders, such as PTSD, fibromyalgia, anxiety and TBI by applying electrical impulses to the vagus nerve according to a stimulation protocol that includes at least two doses each day.

08:11 EDT Dayforce selected by Cleveland Cavaliers to lead workforce transformation - Dayforce announced the Cleveland Cavaliers have chosen Dayforce to help drive simplicity, collaboration, and workforce modernization at scale. With Dayforce, the Cavaliers will accelerate their journey as an innovation leader by harnessing one holistic platform for payroll, benefits administration, workforce management, onboarding, recruiting, and compensation management. The partnership between the Cavaliers and Dayforce was driven by a desire to enhance the workplace experience for their team members through modern HCM technology.

08:09 EDT NeoGames extends agreement with SAZKA - NeoGames has announced a three-year contract extension with its long-standing Czech lottery customer, SAZKA, with the agreement to remain in effect until the end of 2028. SAZKA, a part of Allwyn, is a multi-national lottery operator with leading market positions in the Czech Republic, Austria, Greece, Cyprus, Italy, the United Kingdom, and the United States. The agreement ensures that SAZKA will continue to leverage NeoGames' industry-leading iLottery and iGaming solutions, including its market-leading NeoSphere platform and a diverse portfolio of interactive games. The contract renewal will also see SAZKA integrate content aggregation into its offering, to be supplied by NeoGames' subsidiary Pariplay, with the addition set to significantly enhance the lottery's online gaming offering. Moti Malul, CEO of NeoGames, said: "We consider SAZKA one of our most important and strategic customers, so we are thrilled about this extension. SAZKA has made remarkable growth in its online lottery channels, and we are proud to manage the operator's entire digital activity, providing seamless operational support as it navigates the many regulatory changes taking place across the continent."

08:08 EDT Fractyl Health appoints Kimber as Chief Commercial Officer - Fractyl Health announced the appointment of Adrian Kimber as Chief Commercial Officer. Kimber joins Fractyl with over two decades of experience in the biotechnology and medical devices sectors. Kimber most recently served as Global VP & Commercial Head at Biotronik Neuro, where he spearheaded the introduction of daily remote monitoring and Proactive Care for patients with spinal cord stimulation devices.

08:07 EDT VBI Vaccines broadens deal with Canada on mRNA-launched vaccines - VBI Vaccine announced that it has expanded its collaboration with the government of Canada, supported by a funding contribution from the government's Strategic Innovation Fund or SIF . Under the new agreement, the remaining CAD$28M of funding available under the previously committed $56M will be directed toward the development of VBI's proprietary MLE platform, a next-generation version of the Company's particulate, enveloped virus-like particle or eVLP vaccine technology that enables the coding of eVLPs using messenger RNA, mRNA . In preclinical studies, VBI's MLE candidates generated strong B-cell and T-cell signals compared to those seen with other mRNA vaccines tested. The technology platform also offers potential for streamlined manufacturing timelines, similar to other mRNA vaccines. "We are grateful for the continued support of our long-term partners in the Canadian government, and are pleased to extend our work together to investigate our novel MLE platform, which we think has the potential to revolutionize particulate vaccines," said Jeff Baxter, President and CEO of VBI. "This funding will enable us to validate and expand this technology, one that we believe could have broad applicability." Additionally, in collaboration with the National Research Council of Canada, the partnership will also support the development of stable cell lines, using proprietary gene-editing techniques to enable rapid updates depending on viral target, as well as the optimization of manufacturing timelines, processes, and yields sufficient to support late-stage clinical studies. Consistent with the strategic intent of the original agreement, development will primarily focus on platform development and will also include a pan-coronavirus MLE candidate to contribute toward future epidemic and pandemic preparedness.

08:07 EDT Gorilla, in partnership with Protactics, secures contract in Colombia - Gorilla Technology Group announced its recent success in securing a significant contract to implement its Security Convergence Smart City Video Analytics Solutions in the Casanare province of Colombia. This venture is conducted in close collaboration with esteemed partner Protactics, who will be instrumental in establishing a state-of-the-art intelligence center within the province. "We are proud to be chosen alongside Protactics by the Government of Colombia, to deliver this critical infrastructure to the government of Casanare," said Dr. Raj Natarajan, CTO of Gorilla. "This project is not just about enhancing safety; it's about setting a precedent for how AI technologies can catalyze meaningful change. We're eager to demonstrate our capabilities and contribute to a safer, smarter future for the citizens of Casanare and beyond."

08:06 EDT Vuzix announces reseller agreement with Purview Services - Vuzix announced that it recently entered into a reseller agreement with Purview Services, an IT services, consulting, and business solutions firm based in Edinburgh, Scotland. Vuzix has received and shipped against a large volume purchase order from Purview, who will distribute Vuzix products to its customers across EMEA and India. Through this reseller partnership, Purview intends to offer its customers voice-driven AI solutions using Vuzix AR smart glasses to solve complex business problems. These can vary from remote surveillance of solar and wind farms by field workers, accelerated learning of industrial workforce through AR bots, remote healthcare & ICU support by specialists and making the world a more secure place with enhanced collaboration for defense forces using AR vision headgear. Purview will be targeting industry verticals and develop AI solutions for healthcare, utilities, manufacturing, logistics and defense.

08:05 EDT Clearwater Analytics to acquire certain assets from Wilshire Advisors - Clearwater Analytics announced that it has entered into a definitive agreement to acquire risk and performance analytics solutions from Wilshire Advisors, a global financial services firm. Specifically, Clearwater will acquire Wilshire AxiomS, Wilshire Atlas, Wilshire Abacus, and Wilshire iQComposite, which provide fixed income analytics, equity analytics and performance measurement, accounting, and GIPS compliance support analytics, respectively, and will merge them with its own risk and performance analytics platform to create a powerful and compelling product for its customers. The partnership, which will be co-branded as Clearwater Wilshire Analytics, will allow both companies to provide enhanced analytical capabilities for investment managers and institutional asset owners such as public pension plans, insurers, foundations, endowments and more. Partnering with Wilshire, Clearwater will be able to deepen and strengthen its position in the institutional asset owner market. The transaction is expected to close in the second quarter of 2024, subject to customary closing conditions.

08:03 EDT Mira provides update on pre-clinical studies of Ketamir-2 - MIRA Pharmaceuticals shares updates on the ongoing pre-clinical studies of its investigational compound, Ketamir-2, a novel oral ketamine analog which could potentially deliver ultra-rapid antidepressant effects. MIRA is conducting pre-clinical studies of Ketamir-2 in collaboration with Frontage Laboratories as a potential treatment for individuals battling treatment-resistant depression, or TRD, major depressive disorder with suicidal ideation, or MDSI, and post-traumatic stress disorder, or PTSD. MIRA is hopeful that the encouraging results of these most recent studies will enable MIRA to file an Investigational New Drug Application, or IND, with the FDA by the end of this year which, if accepted, would allow for human testing of Ketamir-2. The latest in vitro research focused on Ketamir-2's stability in the bloodstream, its metabolism, and how it binds to proteins in the blood. These factors play a crucial role in determining a drug's adequacy and likelihood for acceptable safety, its pharmacological profile and potential modes of administration to patients. Ketamir-2 demonstrated excellent stability in blood from various species, including humans. The studies indicate the potential for Ketamir-2 to be metabolized effectively and safely. Ketamir-2 appears to bind optimally to blood proteins, which suggests the potential for effective delivery throughout the body. Initial toxicology assessments provide a favorable safety profile crucial for advancement through regulatory review and clinical trials.

08:02 EDT Gan Limited names Brian Chang CFO - Gan Limited announced that Brian Chang has recently been named the company's CFO. Chang had previously been serving in an interim capacity. Chang will be focused on guiding the company towards a timely closing with Sega Sammy Creation, Inc. Chang has served as the company's interim CFO since November 2022.

08:00 EDT Verve Therapeutics down 33% at $8.50 after pausing Heart-1 trial of VERVE-101

07:52 EDT SLB announces agreement to acquire ChampionX in all-stock transaction - SLB (SLB) and ChampionX Corporation (CHX) announced a definitive agreement for SLB to purchase ChampionX in an all-stock transaction. The agreement was unanimously approved by the ChampionX board of directors. Under the terms of the agreement, ChampionX shareholders will receive 0.735 shares of SLB common stock in exchange for each ChampionX share. At the closing of the transaction ChampionX shareholders will own approximately 9% of SLB's outstanding shares of common stock. "Our customers are seeking to maximize their assets while improving efficiency in the production and reservoir recovery phase of their operations," Olivier Le Peuch, SLB's chief executive officer, said. "This presents a significant opportunity for service providers who can partner with customers throughout the entire production lifecycle, offering integrated solutions and delivering differentiated value. The combination of ChampionX's strong production-focused leadership throughout North America and beyond with our own international presence, unmatched technology portfolio, and history of innovation will drive tremendous value for our customers and stakeholders.

07:50 EDT Appili Therapeutics signs definitive agreement to be acquired by Aditxt - Appili Therapeutics (APLIF) announced that it has entered into a definitive arrangement agreement pursuant to which Aditxt (ADTX), through its wholly-owned subsidiary, Adivir, agreed to acquire all of the issued and outstanding Class A common shares of Appili by way of a court-approved plan of arrangement under the Canada Business Corporations Act. Under the terms of the Arrangement Agreement, shareholders of Appili will receive 0.002745004 of a share of common stock of Aditxt and US$0.0467 for each Appili Share held representing implied total consideration per Appili Share of approximately US$0.0561 based on the closing price of the Aditxt shares on March 28, 2024. The Transaction Consideration represents an approximately 117% premium to the trading price of the Appili Shares based on the closing price of the shares of Appili on April 1, 2024 and an approximately 141% premium to the 30-day volume weighted average price of the Appili Shares prior to the date of the Arrangement Agreement. The Transaction is expected to enhance the combined entity's portfolio of products and potentially create substantive synergies among existing programs, particularly precision diagnostics.

07:46 EDT Kiniksa announces development indication for abiprubart - Kiniksa Pharmaceuticals announced plans to initiate a Phase 2b trial with abiprubart in Sjogren's Disease. Additionally, the company announced data from Cohort 4 of the Phase 2 clinical trial of abiprubart in rheumatoid arthritis. Abiprubart is an investigational humanized anti-CD40 monoclonal antibody designed to inhibit CD40-CD154 interaction. "We believe abiprubart has the potential to provide meaningful benefit to patients suffering from Sjogren's Disease, a debilitating disorder with no current FDA-approved therapies. Based on the clear biological activity demonstrated by abiprubart, potential for convenient subcutaneous administration, and external proof-of-concept of inhibition of the CD40-CD154 interaction, we plan to initiate a Phase 2b trial of abiprubart in Sjogren's Disease in the second half of 2024," said Sanj K. Patel, Chairman and Chief Executive Officer of Kiniksa. "Supported by our robust ARCALYST revenue growth and current cash position, we continue to execute a strategic and disciplined capital allocation approach in areas we believe provide the best opportunity to drive long-term value. Based on our current operating plan, which includes advancement of abiprubart through Phase 3 development in Sjogren's Disease, we expect to remain cash flow positive on an annual basis."

07:38 EDT Lilium begins integration of Garmin standby flight instruments for jet - Lilium (LILM) announced that it has received the first set of standby flight instruments from Garmin (GRMN), a leading provider of avionics solutions. The deliveries, which follow the multi-year supplier contract signed by Lilium and Garmin in 2023, will be integrated into the first Lilium Jets being produced and the Lilium Jet flight simulator, used for pilot training. In aviation parlance, standby instrumentation is intended to serve as a backup display in case of a failure of the primary cockpit instrumentation. Lilium began assembly of the first Lilium Jet at its manufacturing and testing facilities near Munich at the end of 2023. The first piloted flight test of the Lilium Jet is targeted to occur in late 2024.

07:36 EDT Arch Biopartners adds 3 new clinical sits into Phase II trial of LSALT peptide - Arch Biopartners announced that three additional clinical sites in Turkey have joined the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury. LSALT peptide is the Company's lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver. The three new hospitals joining the Phase II study are Istanbul University-Cerrahpaa, Sutcu mam University Hospital in the city of Kahramanmara, and the Gazi University Hospital in Ankara, the capital of Turkey. The trial now has a total of seven clinical sites across Turkey and Canada.

07:35 EDT Coda Octopus reports Echoscope technology used on ongoing salvage operations - Coda Octopus Group reported that its Echoscope technology is being used on the ongoing salvage operations. Commenting on this, Blair Cunningham, CODA's President of Technology, stated "we are humbled and pleased that Coda Octopus and its technology can play a part as the primary survey tool in these ongoing operations, and I am pleased that I can be onsite assisting in the ongoing operations. As noted by SUPSALV in the article referred to above, the conditions are challenging and compounded by poor visibility water conditions ...the Echoscope "is the primary survey tool used by divers, with visibility clouded to just one to two feet because of the four to five feet of mud and loose bottom of the Patapsco River".

07:35 EDT Origin Agritech estimates 1H24 revenue growth of 30%-40% - Origin Agritech provided an update on its financial and operational performance. Origin Agritech reported an estimated half-year revenue of RMB 85M-95M, an increase of 30-40% compared to the same period in the previous fiscal year.

07:32 EDT CME Group reached ADV of 24.3M contracts in March - CME Group reported its March and Q1 2024 market statistics, showing average daily volume reached 24.3M contracts in March and 26.4M contracts in Q1. Reference Link

07:23 EDT Traws Pharma announces new employee inducement grants - Traws Pharma (TRAW) announced it has granted equity awards to new employees who joined Traws in connection with the recent acquisition of Trawsfynydd Therapeutics by Onconova Therapeutics (ONTX). On April 1, 2024, Traws granted restricted stock equity awards to Werner Cautreels, Iain Dukes, Nikolay Savchuk, C. David Pauza and Robert Redfield, as an inducement for each of them to accept employment, which equity awards relate to, 200,000, 67,500, 67,500, 97,500 and 97,500 shares of Traws common stock. One-quarter of the shares subject to each restricted stock equity award will vest on each of the first four anniversaries of the grant date, conditioned upon each employee's continued employment on the vesting date.

07:21 EDT Gilat Satellite's DataPath awarded $12M contract extension from U.S. Army - Gilat Satellite Networks announced that the United States Army awarded a $12 million contract to its subsidiary DataPath, Inc., for the continuation of a program to sustain anytime, anywhere satellite connectivity. The contract is for the supply of Wavestream's Solid State Amplifier products. Wavestream SSPAs are ruggedized to withstand the harshest environments, enabling the Satellite Transportable Terminals used in this program to deliver a "Communications-on-the-Pause" solution across diverse climates and conditions around the globe.

07:19 EDT Perella Weinberg Partners announces Higley joined firm as Partner - Perella Weinberg Partners (PWP) announced that David Higley has joined the Firm as a Partner in the Advisory Business. Higley joins Perella Weinberg from Lazard (LAZ), where he served as a Managing Director and the Global Head of the Interactive Media and Technologies Group, advising clients on mergers and acquisitions, capital raising and strategic advisory.

07:16 EDT Autolus Therapeutics announces acceptance of MAA by EMA for obe-cel - Autolus Therapeutics announces that the European Medicines Agency, EMA, has accepted the Company's Marketing Authorization Application, MAA, for obecabtagene autoleucel, obe-cel. Obe-cel is Autolus' lead investigational chimeric antigen receptor T cell therapy, for the treatment of patients with relapsed/refractory adult B-cell Acute Lymphoblastic Leukemia. The MAA submission was based on data from the pivotal Phase 2 FELIX study of obe-cel in adult r/r B-ALL. Autolus' Nucleus site has recently received the formal certification from the MHRA following a full inspection of the site in February 2024. The MHRA issued two new GMP certificates to cover both clinical and commercial manufacture from the site. "Along with the recent acceptance of the BLA by the FDA, the acceptance of our EU marketing application is an important milestone in expanding into the European market and delivering this potentially transformative therapy to B-ALL patients," commented Dr. Christian Itin, Chief Executive Officer of Autolus. "We look forward to working with the EMA throughout the evaluation process of obe-cel, and thank the internal team at Autolus for their work on the submission and Nucleus site inspection."

07:15 EDT Roivant Sciences announces NEPTUNE study met primary efficacy endpoint - Roivant and Priovant Therapeutics announced positive results from the Phase 2 study evaluating brepocitinib in non-anterior non-infectious uveitis, NIU, showing the strongest efficacy data in NIU observed to date. The NEPTUNE study enrolled 26 subjects with active NIU who were randomized 2:1 to brepocitinib 45 mg once daily or brepocitinib 15 mg once daily. The study's primary efficacy endpoint was the Treatment Failure rate at week 24. At week 24, 29% of subjects in the brepocitinib 45 mg arm and 44% of subjects in the brepocitinib 15 mg arm met Treatment Failure criteria, with lower failure rates reflecting greater treatment benefit. The Treatment Failure rate from disease activity was 18% in the brepocitinib 45 mg arm. These observed results represent approximately twice the observed benefit as seen in the corresponding registrational study for the only approved non-steroidal therapy in NIU. All week 24 secondary efficacy endpoints, including haze grades, visual acuity, and macular thickness, were also positive and dose responsive. Of patients in the brepocitinib 45 mg arm who met the threshold for uveitic macular edema at baseline, 43% achieved resolution of macular edema by week 24. No patients in the brepocitinib 45 mg arm who entered the study without macular edema developed macular edema by week 24. Safety and tolerability were consistent with prior clinical studies of brepocitinib, with no new safety or tolerability signals identified.

07:12 EDT Verve Therapeutics pauses enrollment in Heart-1 trial of VERVE-101 - Verve Therapeutics announced updates from the Heart-1 Phase 1b clinical trial of VERVE-101 and clearance of its Clinical Trial Applications by the U.K. Medicines and Healthcare products Regulatory Agency and Health Canada for VERVE-102, with the Heart-2 Phase 1b clinical trial expected to initiate in the second quarter of this year. VERVE-101 is being evaluated in the Heart-1 Phase 1b clinical trial with trial endpoints of safety and tolerability as well as changes in blood PCSK9 protein and low-density lipoprotein cholesterol levels in patients living with heterozygous familial hypercholesterolemia, established atherosclerotic cardiovascular disease, and uncontrolled hypercholesterolemia. Six participants have been dosed at 0.45 mg/kg of VERVE-101, with a total of 13 participants dosed in the study. For the first five participants in the 0.45 mg/kg cohort with follow-up to at least 28 days, VERVE-101 demonstrated time-averaged LDL-C reductions ranging from 21% to 73%, and averaging 46%. In the two patients with the longest follow-up in the 0.45 mg/kg or 0.6 mg/kg cohorts, LDL-C lowering has been durable out to 270 days, with follow-up ongoing. However, the sixth participant treated in the 0.45 mg/kg cohort experienced a Grade 3 drug-induced transient increase in serum alanine aminotransferase as well as a serious adverse event of Grade 3 drug-induced thrombocytopenia within the first four days after dosing. In light of such observed laboratory abnormalities associated with VERVE-101, Verve, in consultation with the study's independent data and safety monitoring board, has decided to pause enrollment in the Heart-1 clinical trial. Verve is conducting an investigation into the laboratory abnormalities and based on those results, expects to work with regulatory authorities to define a path forward for VERVE-101. These safety events were reported to the U.S. Food and Drug Administration, MHRA, and the New Zealand Medicines and Medical Devices Safety Authority (Medsafe). The VERVE-101 Investigational New Drug Application and other CTAs remain active. Verve is now prioritizing the development of VERVE-102 and the initiation of the Heart-2 clinical trial.

07:10 EDT Ginkgo Bioworks acquires Modulus Therapeutics' cell therapy platform assets - Ginkgo Bioworks announced the acquisition of Modulus Therapeutics' cell therapy platform assets, including their chimeric antigen receptor, or CAR, and switch receptor libraries. Modulus Therapeutics is a cell engineering company focused on the design of next-generation cell therapies for autoimmune diseases. In contrast to legacy cell therapy design, the company uses a combinatorial approach to build and screen cell therapy components that work in concert with one another to yield novel cell behaviors. Modulus has used its platform to develop and screen libraries of novel NK-specific and T-cell specific CAR and switch receptor designs, which enable improved control and performance of immune cell-based therapies. Modulus' assets complement Ginkgo's extensive cell therapy capabilities. With this addition, Ginkgo looks forward to supporting its customers who are improving the performance of T-cell and NK-cell based CAR therapies to treat solid tumors, autoimmune, and other diseases.

07:08 EDT Montrose Environmental acquires ETA, terms undisclosed - Montrose Environmental announced the acquisition of Engineering & Technical Associates, or ETA, a company in Process Safety Management. ETA will join Montrose's Assessment, Permitting & Response segment.

07:07 EDT Avalo Therapeutics appoints Kantoff, Goldman, Truex as independent directors - Avalo Therapeutics announced the addition of multiple biotech leaders to its Board of Directors. The Avalo Board brings together a team with expertise spanning finance, business operations, drug discovery and clinical development. The recent board appointments include Aaron Kantoff, Jonathan Goldman, and Samantha Truex as Independent Directors.

07:06 EDT Bio-Path provides 2024 clinical, operational update - Bio-Path Holdings provides a clinical development and operational update for 2024. Bio-Path's clinical development program consists of one Phase 2 clinical trial and three Phase 1 or 1/1b clinical trials. Bio-Path is developing a molecular biomarker package to accompany prexigebersen treatment and expects to evaluate prexigebersen for the treatment of obesity. Development of Molecular Biomarkers - Bio-Path is developing a molecular biomarker package to accompany prexigebersen treatment, the goal of which is to identify patients with a genetic profile more likely to respond to treatment thereby improving probability of success for this program. Prexigebersen Phase 2 Clinical Trial - Bio-Path's Phase 2 clinical trial is treating Acute Myeloid Leukemia patients. This trial is comprised of three separate cohorts of patients and treatments, each separately approvable by the FDA as a new drug indication. Phase 1/1b Clinical Trial in BP1001-A in Advanced Solid Tumors - A Phase 1/1b clinical trial of BP1001-A in patients with advanced or recurrent solid tumors, including ovarian and uterine, pancreatic and breast cancer, is ongoing. Phase 1/1b Clinical Trial in BP1002 in Relapsed/Refractory AML - A Phase 1/1b clinical trial for BP1002 to treat relapsed/refractory AML patients, including venetoclax-resistant patients, is ongoing. Phase 1 Clinical Trial in BP1002 in Refractory/Relapsed Lymphoma and Chronic Lymphocytic Leukemia - A Phase 1 clinical trial to evaluate the ability of BP1002 to treat refractory/relapsed lymphoma and refractory/relapsed chronic lymphocytic leukemia patients is currently ongoing. Preclinical Work for BP1003 - The Company continues to advance its drug candidate, BP1003, for the treatment of advanced solid tumors, including pancreatic cancer. Prexigebersen as Potential Treatment for Obesity and Obesity-related Cancers - The RNAi target of prexigebersen is the Grb2 protein, which is involved in activating the RAS/ERK pathway for cell growth. Bio-Path believes development of prexigebersen for the treatment for obesity and obesity-related cancers could be accelerated given the large amount of safety data from prexigebersen treatment of leukemia patients and the continued unmet medical need. The Company expects to evaluate prexigebersen for the treatment of obesity as soon as corporate resources are sufficient.

07:04 EDT AstraZeneca, Daiichi Sankyo datopotamab deruxtecan BLA accepted in the U.S. - AstraZeneca and Daiichi Sankyo's Biologics License Application, or BLA, for datopotamab deruxtecan, or Dato-DXd, has been accepted in the U.S. for the treatment of adult patients with unresectable or metastatic hormone receptor-positive, HER2-negative breast cancer who have received prior systemic therapy for unresectable or metastatic disease. The Prescription Drug User Fee Act date, the FDA action date for its regulatory decision, is during the first quarter of 2025.

07:01 EDT Plymouth Industrial REIT provides activity update for Q1 - Plymouth Industrial REIT announced its leasing and development activity for the first quarter of 2024. The Company also announced details for its first quarter earnings conference call and webcast to be held on May 2, 2024. Jeff Witherell, Chief Executive Officer and Co-Founder of Plymouth, noted, "We continue to make progress on our 2024 leasing opportunities with a 17.1% increase on a cash basis for the quarter, nearly 56% of our 2024 expirations already addressed and our development program now 93% leased." Leases commencing during the first quarter ended March 31, 2024 totaled an aggregate of 1,387,977 square feet, all of which are associated with terms of at least six months. The final project in the first phase of Plymouth's development program, a 52,920-square-foot, fully leased building in Jacksonville, is expected to come online in the third quarter of 2024.

06:47 EDT e.GO to file application for opening of insolvency proceedings - Next.e.GO N.V., the parent company of Next.e.GO Mobile SE, announced its decision to also file an application for opening of insolvency proceedings with the competent district court of Aachen. The decision to apply for the opening of the insolvency proceedings with the competent court follows the previously disclosed filing of the application for opening of insolvency proceedings by Next.e.GO Mobile SE, the main subsidiary of Next.e.GO N.V. This comes amidst a backdrop of recent adverse developments and challenges across the electric vehicle industry and volatility in the capital markets, exacerbated by the recent situation surrounding other players in the EV sector. Moreover, given the unfavorable market environment, the equity-based financing instruments that were secured by the Company could not perform to the expected level and pace; and despite significant efforts by the Company, the prevailing market conditions along with uncertainty across the EV sector have further significantly hindered the Company's ability to secure alternative funding as required under the local regulatory framework.

06:44 EDT Qifu Technology provides update on share repurchase plan - Qifu Technology provided updates on its share repurchase plans. On June 20, 2023, the Company announced a share repurchase plan whereby the Company is authorized to repurchase its American depositary shares, or ADSs, or Class A ordinary shares with an aggregate value of up to $150M during the 12-month period from June 20, 2023. As of March 28, 2024, the Company had utilized substantially all of the total authorized value for the 2023 Share Repurchase Plan----the Company had in aggregate purchased 9,348,543 ADSs in the open market for a total amount of $149,979,804 at an average price of $16.02 per ADS pursuant to the plan. The Company intends to cancel all of the repurchased shares in accordance with applicable rules and regulations.

06:39 EDT Cheer Holding acquires national patent for Method and System for NFT Trading - Cheer Holding announced the acquisition of a national patent certificate for its "Method and System for NFT Trading" from the National Intellectual Property Office. This pioneering invention tackles the security challenges and content protection limitations present in digital collectible transactions, ensuring both transactional security and content integrity for digital collectibles. By enabling secure and seamless transactions and transfers of non-fungible tokens, or NFTs, this achievement solidifies the Company's position as an industry powerhouse in the field of blockchain technology. The patented invention encompasses various aspects of NFT trading technology, including robust buyer and seller authentication, precise grayscale analysis of authenticated seller's digital collectible frame images to extract the unique address code associated with each digital collectible.

06:37 EDT Terran Orbital's Tyvak International secures European defense agency contract - Tyvak International SRL, a Torino, Italy-based subsidiary of Terran Orbital, announced a secured service subcontract for the European Defense Agency's Hub for EU Defense Innovation proof-of-concept prototype 2023. This groundbreaking project focuses on Very Low Earth Orbit satellite exploration, marking a significant leap forward in military space technology. The contract encompasses Phase A of the LEO to VLEO spacecraft, culminating in a Preliminary Design Review. Tyvak International will play a leading role within a consortium including prime contractor CNIT, collaborating with FlySight and Politecnico di Milano.

06:35 EDT GE Aerospace announces official launch as an independent public company - GE Aerospace (GE) announced its official launch as an independent public company defining the future of flight, following the completion of the GE Vernova spin-off. GE Aerospace will trade on the New York Stock Exchange under the ticker "GE". On April 2 at 9:30 a.m. ET, GE Aerospace and GE Vernova (GEV) will ring the opening bell together at the NYSE.

06:31 EDT Trivago appoints Robin Harries as CFO - trivago announced the completion of its leadership change with the arrival of newly appointed CFO Robin Harries, effective April 1. Harries' expertise will complement and enrich the new leadership team tasked with implementing a refined strategic focus to unlock value for both users and advertisers. An experienced executive in Finance, Business Development and Marketing, Harries is no stranger to the travel tech business or trivago, having held various leadership positions with the company between 2012 and 2018. Most notably, he played a vital role in the 2012 acquisition by Expedia, leaving trivago in 2018 after leading the company's successful Nasdaq initial public offering in 2016 and driving its global expansion in Asia Pacific.

06:09 EDT Radware to provide advanced DDoS protection for Asian tax authority - Radware announced an Asian tax authority will use Radware's advanced Defense Pro X DDoS protection to increase defenses surrounding its technology infrastructure. The security purchase by the federal authority is part of a million-dollar deal. Chartered to protect its country's economic interests, the tax authority's responsibilities include administering tax policy, managing and securing associated communications and information technologies, and maximizing operational efficiencies.

06:08 EDT Canoo signs vehicle sales agreement with Jazeera Paints - Canoo signed a vehicle sales agreement with Jazeera Paints, a paint manufacturer in the Gulf Cooperation Council and Middle East and North Africa. Jazeera Paints will initially purchase 20 Canoo's electric vehicles into its fleet in 2024, with the option to expand up to 180 additional vehicles. This agreement taps into the Saudi Arabian EV market, which commands a total addressable market of over $30B, and aligns with initiatives within the GCC region to enhance sustainable mobility solutions. These vehicles will be one of Canoo's first international sales exported to Saudi Arabia utilizing Canoo's recently approved Foreign Trade Zone which contributes to lower unit cost and higher margins as announced in Canoo's press release on March 18. In addition, these electric commercial delivery vehicles provide Canoo with a first mover advantage in the Saudi market and a competitive position in the Gulf Cooperation Council region. Jazeera Paints will be deploying Canoo's LDV 130 and LDV 190 delivery vehicles within its existing fleet, which operate throughout the Kingdom of Saudi Arabia and MENA and support Jazeera Paints' commitment to the Saudi Green Initiative's imperative that 30 percent of new car sales in the Kingdom are electric by 2030.

06:05 EDT CareTrust REIT acquires thre CCRCs in Southern California - CareTrust REIT announced that it has purchased three continuing care retirement communities located in Los Angeles, Orange, and San Diego counties. The multi-service senior living campuses include 475 assisted living, skilled nursing, and memory care beds/units. All three facilities will be operated by Bayshire Senior Communities, an existing CareTrust tenant based in Southern California. The investments were funded using cash on hand.

06:04 EDT Warner Bros. Discovery reports resignation of Miron, Newhouse from board - In a regulatory filing, Warner Bros. Discovery said that on March 29, Steven A. Miron and Steven O. Newhouse notified the Warner Bros. Discovery board of directors of their decision to resign from the company's board and its committees, effective as of March 29. Miron was a member of the company's Compensation Committee and Newhouse was a member of the company's Nominating and Corporate Governance Committee. The resignations were not the result of any disagreement with the company on any matter relating to the company's operation, policies or practices. Following the receipt of Miron's and Newhouse's resignations, on April 1, the board adopted a resolution to reduce the size of the Board to eleven directors.

05:20 EDT Ashford to terminate SEC registration, delist shares from NYSE - Ashford announced that a special committee of independent and disinterested directors has recommended, and its board has approved, a plan to terminate the registration of the company's common stock under the federal securities laws following the completion of a proposed reverse stock split transaction immediately followed by a forward stock split transaction and to delist its shares of common stock from trading on the NYSE American. It is expected that this plan would be initiated in the summer of 2024, subject to Ashford's stockholders approving the proposed transaction at a special meeting of stockholders to be held for that purpose. Ashford is taking these steps to avoid the substantial cost and expense of being a public reporting company and to focus the company's resources on enhancing long-term stockholder value. The company anticipates savings exceeding $2,500,000 on an annual basis as a result of the proposed transaction.

05:11 EDT AllianceBernstein, Societe Generale launch Bernstein joint venture - AllianceBernstein (AB) and Societe Generale (SCGLY) announced the official launch of Bernstein, a joint venture creating a global cash equities and equity research business. The creation of Bernstein follows the original announcement of the plan to form the joint venture in November 2022. Bernstein provides institutional investors, corporates and financial institutions with investment insights into North American, European and Asia Pacific equity markets, in addition to liquidity access and global trading technology. With Bernstein, Societe Generale will now offer its clients a suite of global services across the equities value-chain, from equity and macro research to agency execution, equity derivatives, prime brokerage, and equity capital markets offerings. With over 750 employees serving clients globally, the joint venture is organized under two separate legal vehicles with a Head Office in New York covering North America and a Head Office in London covering Europe and Asia, complemented by major hubs in Paris and Hong Kong, and multiple regional offices. The ultimate objective of Societe Generale and AllianceBernstein is for Societe Generale to eventually own 100% of both entities after five years*. Robert van Brugge, previously CEO of Bernstein Research Services, has been appointed CEO of Bernstein, with Stephane Loiseau, previously Head of Societe Generale's cash equities business, appointed Deputy CEO of Bernstein. The closing of the transaction has been approved by the relevant regulatory and antitrust authorities. The new brand capitalizes on the Bernstein name with a Societe Generale Group byline: